Indaptus Therapeutics (INDP)
NASDAQ:INDP
Total Valuation
Indaptus Therapeutics has a market cap or net worth of $3.99M. The enterprise value is -$5.39M.
Market Cap$3.99M
Enterprise Value-$5.39M
Share Statistics
Indaptus Therapeutics has 2,242,324 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding2,242,324
Owned by Insiders21.89%
Owned by Institutions0.85%
Financial Efficiency
Indaptus Therapeutics’s return on equity (ROE) is -6.62 and return on invested capital (ROIC) is -629.32%.
Return on Equity (ROE)-6.62
Return on Assets (ROA)-2.24
Return on Invested Capital (ROIC)-629.32%
Return on Capital Employed (ROCE)-6.29
Revenue Per Employee0.00
Profits Per Employee-2.98M
Employee Count7
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Indaptus Therapeutics is ―. Indaptus Therapeutics’s PEG ratio is -0.00011.
PE Ratio―
PS Ratio0.00
PB Ratio0.89
Price to Fair Value0.89
Price to FCF-0.19
Price to Operating Cash Flow-0.25
PEG Ratio-0.00011
Income Statement
In the last 12 months, Indaptus Therapeutics had revenue of 0.00 and earned -20.85M in profits. Earnings per share was -21.58.
Revenue0.00
Gross Profit0.00
Operating Income-19.83M
Pretax Income-20.85M
Net Income-20.85M
EBITDA-19.83M
Earnings Per Share (EPS)-21.58
Cash Flow
In the last 12 months, operating cash flow was -15.31M and capital expenditures 0.00, giving a free cash flow of -15.31M billion.
Operating Cash Flow-15.31M
Free Cash Flow-15.31M
Free Cash Flow per Share-6.83
Dividends & Yields
Indaptus Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.95
52-Week Price Change-88.44%
50-Day Moving Average2.02
200-Day Moving Average4.52
Relative Strength Index (RSI)45.17
Average Volume (3m)1.08M
Important Dates
Indaptus Therapeutics upcoming earnings date is May 7, 2026, Before Open (Confirmed).
Last Earnings DateMar 12, 2026
Next Earnings DateMay 7, 2026
Ex-Dividend Date―
Financial Position
Indaptus Therapeutics as a current ratio of 1.51, with Debt / Equity ratio of 0.00%
Current Ratio1.51
Quick Ratio1.51
Debt to Market Cap0.00
Net Debt to EBITDA0.43
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Indaptus Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Indaptus Therapeutics EV to EBITDA ratio is 0.29, with an EV/FCF ratio of 0.38.
EV to Sales0.00
EV to EBITDA0.29
EV to Free Cash Flow0.38
EV to Operating Cash Flow0.38
Balance Sheet
Indaptus Therapeutics has $8.51M in cash and marketable securities with $0.00 in debt, giving a net cash position of $8.51M billion.
Cash & Marketable Securities$8.51M
Total Debt$0.00
Net Cash$8.51M
Net Cash Per Share$3.79
Tangible Book Value Per Share$3.26
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Indaptus Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast34.57%